---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Place in treatment, anticipated use, and care setting. Topics: Summary: severity definitions and candidacy for systemic therapy; Summary: guideline positions on first systemic therapy and oral agents; Summary: oral agents, head-to-head evidence, and the comparative evidence for envudeucitinib; Guideline recommendation for the first systemic therapy: a biologic with a first-line label or deucravacitinib; 10 further topics. 14 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: severity definitions and candidacy for systemic therapy

- The German S3 guideline adapted from EuroGuiDerm (Nast et al.) defines mild psoriasis as “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” and moderate to severe psoriasis as “(BSA > 10 or PASI > 10) and DLQI > 10”. Mild disease is upgraded to moderate-to-severe by major involvement of visible areas or the scalp, involvement of the genitals, palms, or soles, onycholysis or onychodystrophy of at least two fingernails, pruritus leading to scratching, or recalcitrant plaques. Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15, rapid deterioration, and severe involvement of the hands and/or feet, scalp, face, nails, or genitals.
- The most preferred statement reported by Strober et al. classifies patients as candidates for topical therapy or candidates for systemic therapy; the latter meet at least one of three criteria: body surface area >10%, disease involving special areas, or failure of topical therapy.
- The National Psoriasis Foundation classifies a patient as having mild psoriasis, managed with topical therapies, or moderate-to-severe psoriasis, which makes the patient a candidate for advanced therapies, including phototherapy and modern systemic treatments; it states that current systemic treatments include oral and biologic therapies.
- The deucravacitinib label indicates it for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the icotrokinra label for the same population and for pediatric patients 12 years of age and older who weigh at least 40 kg, and the apremilast label for adults with plaque psoriasis who are candidates for phototherapy or systemic therapy. Trials PSO-1 and PSO-2 of the icotrokinra label defined moderate-to-severe plaque psoriasis as IGA score ≥3, PASI score ≥12, and BSA involvement ≥10%.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Strober et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31425723/); [National Psoriasis Foundation position statement on psoriasis severity (2025)](https://www.psoriasis.org/position-statement-on-psoriasis-severity/); [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.2-2"></a>

### Summary: guideline positions on first systemic therapy and oral agents

- EuroGuiDerm-adapted German S3 guideline (Nast et al.): when systemic treatment is initiated for the first time, the guideline suggests a biologic with a first-line label or deucravacitinib, especially for psoriasis of particular severity. It bases this on the disease burden of particularly severe psoriasis and on the results of the Cochrane review, and its classification of first-line and second-line agents follows the approved indications in the summary of product characteristics.
- In the EuroGuiDerm-adapted guideline's summary of the Cochrane network meta-analysis (Nast et al.), infliximab, the anti-IL-17 drugs, and the anti-IL-23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti-TNF alpha agents, and deucravacitinib, and no significant difference was shown between apremilast and ciclosporin or methotrexate. Sbidian et al. state that deucravacitinib and risankizumab were more effective than apremilast and that ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.
- AAD-NPF guideline on systemic nonbiologic therapies (Menter et al.): the guideline states that apremilast “is recommended for the treatment of moderate to severe psoriasis in adults” and describes it as an appropriate choice for patients who prefer to avoid frequent injections and laboratory monitoring and are willing to accept a slower onset of skin clearance and a lower likelihood of clearing. It also recommends methotrexate for moderate to severe psoriasis in adults and cyclosporine for severe, recalcitrant psoriasis.
- Preference for oral therapy: among 397 respondents, avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy. The Alumis corporate presentation states “75% Patients prefer orals over injectables”.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/); [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext); [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.2.2.2-3"></a>

### Summary: oral agents, head-to-head evidence, and the comparative evidence for envudeucitinib

- Oral agents with a U.S. label: deucravacitinib 6 mg once daily; apremilast 30 mg twice daily after a 5-day titration, or the extended-release tablet 75 mg once daily; and icotrokinra 200 mg once daily upon waking on an empty stomach, whose market introduction date is 2026-03-18 in the California HCAI new prescription drugs file. The FDA accepted the zasocitinib NDA under Priority Review, with a PDUFA target action date in the first quarter of calendar year 2027.
- Deucravacitinib versus apremilast: at week 16, PASI 75 was achieved by 58.4% with deucravacitinib, 35.1% with apremilast, and 12.7% with placebo in POETYK PSO-1, and by 53.0%, 39.8%, and 9.4% in POETYK PSO-2.
- Icotrokinra versus deucravacitinib: in Trial PSO-1 of the icotrokinra label, week 16 PASI 90 was achieved by 171 of 311 (55%) icotrokinra and 91 of 307 (30%) deucravacitinib participants and PASI 100 by 97 (31%) and 34 (11%); in Trial PSO-2, week 16 PASI 90 was achieved by 184 (58%) and 111 (34%), while Stein Gold et al. report 184 of 322 (57%) for icotrokinra in ADVANCE 2. Through week 24 of ICONIC-ADVANCE 1 and 2, adverse events occurred in 359 of 632 (57%) icotrokinra and 411 of 634 (65%) deucravacitinib participants.
- Zasocitinib: against deucravacitinib in LATITUDE Atlas (606 participants), week 16 PASI 100 was 36.5% (n=301) and 13.9% (n=303) and PASI 90 was 62.5% and 34.0%. Against apremilast at week 16, PASI 75 was 76% and 37% in LATITUDE PsO 3001 and 71% and 33% in LATITUDE PsO 3002 (Takeda press releases).
- Oral agent versus biologic: in the open-label IMMpactful trial, funded by AbbVie, PASI 90 at week 16 was achieved by 57.3% with risankizumab and 22.9% with deucravacitinib.
- Envudeucitinib: ONWARD1 and ONWARD2 compared envudeucitinib with placebo and apremilast, and STRIDE compared five envudeucitinib doses with placebo. The report holds no head-to-head trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”, and De Luca et al. state that the next-generation agents have been compared with placebo, apremilast, or deucravacitinib and have not been compared with IL-17 or IL-23 inhibitors. The Alumis corporate presentation compares PASI 100 rates of envudeucitinib (ONWARD1 and ONWARD2 at week 24), icotrokinra, and zasocitinib across trials and states that the results of this “retrospective post hoc cross-trial comparison may not be directly comparable”.
- Care setting: Alumis states that its success will depend upon physicians specializing in the treatment of the targeted diseases prescribing its product candidates. A single-center retrospective review drew on referrals for specialty medications by dermatology providers for psoriasis or atopic dermatitis and on the specialty pharmacy patient management system. In the United States, access to dermatologists “is limited in many regions”, especially in underserved and rural communities.

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/); [Armstrong et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/35820547/); [Strober et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36115523/); [Stein Gold et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40976249/); [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/); [Magnolo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13280295/); [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/); [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4); [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm); [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/); [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

<a id="topic-2.2.2.2-4"></a>

### Guideline recommendation for the first systemic therapy: a biologic with a first-line label or deucravacitinib

> “If systemic treatment of psoriasis is initiated for the first time, we suggest treatment with a biologic with first‐line label or with deucravacitinib, especially for psoriasis of particular severity”
> “We recommend initiating a systemic treatment in patients with moderate to severe psoriasis according to Figure 3.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-5"></a>

### Rationale for the guideline's first systemic therapy recommendation and first-line classification

> “The recommendation IX‐3 on the direct use of first‐line biologics or deucravacitinib is justified by the particularly high disease burden in particularly severe psoriasis and based on the results of the Cochrane review”
> “The classification of agents in 1st line and 2nd line, as presented in Figure 3, was based on the approved indications listed in the summary of product characteristics.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-6"></a>

### PASI 90 likelihood with biologics, deucravacitinib, and apremilast in the guideline summary of the Cochrane network meta-analysis

> “Infliximab, anti‐IL‐17 drugs (bimekizumab, ixekizumab, secukinumab, and brodalumab), and anti‐IL‐23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti‐TNF alpha agents, and deucravacitinib.”
> “No significant difference was shown between apremilast and two non‐biologic drugs: ciclosporin and MTX.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-7"></a>

### National Psoriasis Foundation position on severity and candidacy for oral and biologic systemic therapies

> “Moderate-to-severe psoriasis is not determined solely by body surface area (BSA) involvement of 10%.”
> “These patients are all candidates for advanced therapies, including phototherapy as well as modern systemic treatments.”
> “Today’s systemic treatments include a variety of safe and highly effective oral and biologic therapies that treat inflammation throughout the body.”
> “A patient should be considered as having either 'mild' psoriasis, which can be managed with topical therapies, or a moderate-to-severe psoriasis, which makes these patients candidates for advanced therapies.”

Source: [National Psoriasis Foundation position statement on psoriasis severity (2025)](https://www.psoriasis.org/position-statement-on-psoriasis-severity/)

<a id="topic-2.2.2.2-8"></a>

### Patient preference for oral or topical administration over injections: 397 respondents

> “A total of 397 respondents, with a mean self-assessed Psoriasis Activity and Severity Index score of 8.2 (SD, 9.8), provided data for analysis.”
> “The maximum possible improvement in treatment efficacy offered in the study was not enough to match the improvements in well being associated with some changes in mode of administration.”
> “Avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy.”

Source: [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/)

<a id="topic-2.2.2.2-9"></a>

### Investigator statement on the choice between oral and biologic therapies

> “Patients with moderate-to-severe psoriasis have to choose between oral and biologic therapies”
> “And for individuals seeking the best chance for clearance, biologics have long been superior to oral therapies.”
> “But now, with these new data on envudeucitinib, we’re seeing an exciting possibility of a new oral drug for psoriasis that can deliver high levels of efficacy in a safe manner.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-2.2.2.2-10"></a>

### Manufacturer statements on the intended position of envudeucitinib among oral therapies

> “In Phase 3, this translated into rapid onset of action, high rates of skin clearance, and meaningful symptom improvements that rank among the strongest reported for an oral therapy.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “The depth of clinical response, together with the favorable safety profile observed, underscores a differentiated clinical profile among marketed and investigational oral options and supports envudeucitinib’s potential to play a leading role in the treatment of patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

> “Next-generation orals expected to drive volume growth, powered by multiple brands”
> “Patients and clinicians still seek effective oral therapies”
> “75% Patients prefer orals over injectables”
> “Leading consistent PASI 100 skin clearance amongst oral therapies (ONWARD1/2 at Wk 24)”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.2.2.2-11"></a>

### Prescribing specialists and uptake: manufacturer statement

> “Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing, and their patients being willing to receive, treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.2.2.2-12"></a>

### Care setting: dermatology referral and specialty pharmacy dispensing of targeted therapies

> “A single-center, retrospective review of data collected from electronic health records and the specialty pharmacy patient management system was conducted.”
> “Patients were included if they had a referral for a specialty medication by a dermatology provider for PsO or AD that was discontinued because of the payer/PBM requiring step therapy or formulary alternative use from January 2021 to June 2022.”

Source: [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/)

> “The study included 24,767 patients (535 HCPro; 24,232 non-HCPro).”
> “HCPro patients had a greater frequency of initiation at a specialty pharmacy (66% vs. 56%; P < 0.001) and enrollment in AbbVie’s patient support program (71% vs. 51%; P < 0.001) as well as a lower copay for ADA ($206 vs. $265; P = 0.011).”

Source: [Hawkes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822976/)

<a id="topic-2.2.2.2-13"></a>

### Access to dermatologists in underserved and rural communities

> “In the United States, access to dermatologists is limited in many regions, and this lack of access is especially pronounced among patients in underserved and rural communities”

Source: [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

> “Telemedicine has the potential to allow for collaborative connected-health models to expand the reach of experienced dermatologists to help comanage patients with primary care physicians and community dermatologists who are not comfortable with newer systemic treatments for psoriasis.”

Source: [Pelet Del Toro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10238745/)

<a id="topic-2.2.2.2-14"></a>

### German S3 guideline adapted from the EuroGuiDerm guideline, part 1: scope and approval

> “This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies.”
> “The authors of this work have adapted, remixed, transformed, translated or built upon a previous version of the following article: EUROGUIDERM GUIDELINE FOR THE SYSTEMIC TREATMENT OF PSORIASIS by Nast A et al.”
> “The present adapted guideline did not undergo an approval procedure by the European Dermatology Forum, but has been approved by the editing German societies.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
